
Kaposi's Sarcoma-Associated Herpesvirus Is Not Detected With Immunosuppression in Multiple Myeloma

To the Editor:

Kaposi's sarcoma-associated herpesvirus (KSHV) is involved in the pathogenesis of all forms of Kaposi's sarcoma (KS).1 In acquired immunodeficiency syndrome (AIDS)-associated KS, KSHV detection in peripheral blood mononuclear cells increases with immunosuppression.2 Posttransplant KS are generally due to KSHV reactivation,3 and in peripheral blood mononuclear cells increases with immunosuppression.4 Serologic studies have shown that 80% to 90% of KS patients have detectable antibodies against KSHV. These data clearly demonstrate that KSHV is under immunological control in KS patients.

Recently, KSHV was detected in long-term cultures of bone marrow stromal cells (BMSC) with a phenotype of dendritic cells (DC)5 and in bone marrow (BM) core biopsies from patients with multiple myeloma (MM).6 The physiopathological relevance of KSHV in this interleukin-6 (IL-6)–related disease could be that it encodes for a viral IL-6 (vIL-6) able to stimulate the growth of human MM cell lines.9 However, these results contradict what is known about KSHV infection and MM. These data clearly demonstrate that KSHV is under immunological control in MM patients.10 In addition, five groups reported a lack of antibodies against KSHV antigens in MM patients despite a normal humoral response to other herpesviruses.11-15 Finally, we and others were recently unable to find KSHV in DC samples obtained from apheresis cells of MM patients.16,17 and Masood et al14 failed to detect KSHV DNA in long-term BMSC cultures from MM patients. This discrepancy led us to explore the possibility that an extremely low level of KSHV infection in MM patients, leading to variable detection, may be reactivated during severe immunosuppression.

Ten patients with MM were treated with a double high-dose chemotherapy (HDC; 140 mg/m² melphalan plus 8 Gy total body irradiation) supported by autograft with purified CD34⁺ cells (reinfusion of 4.02 ± 1.03 × 10⁶ CD34⁺/kg; range, 2.88 to 5.73 × 10⁶/kg). CD34⁺ progenitors were purified by the clinical-grade method from Cellpro (Bothell, WA), leading to a 35.6-fold enrichment in hematopoietic progenitors from a mean value of 4.02 ± 1.03 × 10⁶ CD34⁺ cells/kg; range, 2.88 to 5.73 × 10⁶/kg). Four of 10 patients relapsed within 1 year. The peripheral blood CD4⁺ T-cell count was monitored at 3, 6, and 12 months after the second purified autograft. Eight of 10 patients had less than 200 CD4⁺ T cells/µL for at least 3 months, with a mean duration of 7 months for the 6 evaluable over 1 year (Table 1).

Table 1. CD4⁺ T-Cell Counts and Infectious Events in Autografted MM Patients

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Before First HDC</th>
<th>Day 90 After Second HDC</th>
<th>Day 180 After Second HDC</th>
<th>Day 360 After Second HDC</th>
<th>Cumulative Infectious Events After Second HDC⁺</th>
<th>Infectious Events After Second HDC⁺</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of CD4⁺ T Cells/µL</td>
<td>No. of CD4⁺ T Cells/µL</td>
<td>No. of CD4⁺ T Cells/µL</td>
<td>No. of CD4⁺ T Cells/µL</td>
<td></td>
<td>CD4⁺ T-cell count was monitored by flow cytometry. Abbreviation: ND, not done.</td>
</tr>
<tr>
<td>1</td>
<td>892</td>
<td>170</td>
<td>291</td>
<td>266</td>
<td>4</td>
<td>VZV, CMV</td>
</tr>
<tr>
<td>2</td>
<td>361</td>
<td>91</td>
<td>150</td>
<td>146</td>
<td>6</td>
<td>VZV, CMV</td>
</tr>
<tr>
<td>3</td>
<td>350</td>
<td>95</td>
<td>307</td>
<td>234</td>
<td>12</td>
<td>HSV</td>
</tr>
<tr>
<td>4</td>
<td>315</td>
<td>327</td>
<td>150</td>
<td>146</td>
<td>8</td>
<td>HZV, CMV</td>
</tr>
<tr>
<td>5</td>
<td>259</td>
<td>77</td>
<td>75</td>
<td>88</td>
<td>0</td>
<td>HSV</td>
</tr>
<tr>
<td>6</td>
<td>369</td>
<td>168</td>
<td>148</td>
<td>160</td>
<td>12</td>
<td>CMV, Other</td>
</tr>
<tr>
<td>7</td>
<td>430</td>
<td>140</td>
<td>149</td>
<td>†</td>
<td>12/1†</td>
<td>Other</td>
</tr>
<tr>
<td>8</td>
<td>593</td>
<td>310</td>
<td>ND</td>
<td>†</td>
<td>0</td>
<td>CMV</td>
</tr>
<tr>
<td>9</td>
<td>124</td>
<td>64</td>
<td>199</td>
<td>†</td>
<td>6/6†</td>
<td>Other</td>
</tr>
<tr>
<td>10</td>
<td>412</td>
<td>128</td>
<td>†</td>
<td>†</td>
<td>4/4†</td>
<td>CMV</td>
</tr>
</tbody>
</table>

Mean ± SD: 410.5 ± 207.5, 157 ± 92.5, 166.2 ± 99.8, 207.5 ± 94.9

CD4⁺ T-cell count was monitored by flow cytometry. Abbreviation: ND, not done.

† Patient died before evaluation.
²CD4 count could be evaluated only during the indicated time.
³Patient has not reached day 360 after HDC.
been associated with hematopoietic stem cell transplantation, no kinetic study was available; thus, repeated polymerase chain reaction (PCR) amplification was performed to detect KSHV in BM samples harvested before and 90, 180, and 360 days after the second HDC. KSHV DNA was monitored in 1 µg of genomic DNA (ie, 150,000 cells), in a blinded fashion and in two different laboratories, using a PCR assay against the KS330233 KSHV sequence. This sensitive method allowed the detection of KSHV DNA in less than 1 pg of genomic DNA from the KSHV-infected BCBL-1 cell line that corresponds to approximately 5 KSHV genome copies. KSHV DNA was not detected in any of the 35 BM samples tested (Fig 1). The lack of KSHV detection was not due to the presence of Taq polymerase inhibitors, in particular heparin, because the sensitivity of KSHV PCR was the same when assayed with either DNA harvested from heparinized BM mononuclear cells or DNA from cells collected without heparin (Fig 1).

Three explanations may account for the discrepancy between the negative PCR with BM aspirates, the negative serological results, the lack of KSHV reactivation in immunosuppressed MM patients, and the positive PCR with stromal cultures and BM biopsies. (1) MM patients could be infected with a variant of KSHV that can escape the immune system or that encodes for antigens not recognized by the available immunological assays. This could explain the failure to detect anti-KSHV antibodies. (2) KSHV could be under a strict T-cell–mediated immune control in MM patients, leading to a very difficult detection by sensitive PCR. In this case, because infected cells remain undetectable in whole BM samples after double HDC and graft of purified CD34+ cells, one could hypothesize that this treatment has not destroyed anti-KSHV–specific CD4+ and CD8+ T cells, contrary to other anti-herpesvirus T cells. (3) KSHV could not be involved in MM patients, and its detection could be linked to false-positive PCR, as pointed out recently by Moore.

These contradictions need to be elucidated, but our present results emphasize that, if KSHV or a variant of KSHV is really involved in MM, it is not a major factor in relapse occurring in immunosuppressed patients after autologous graft and raises the question of its causal role in MM.

Karin Tarte
IGMM
CNRS
Montpellier, France
Sonja J. Olsen
Division of Epidemiology
Columbia University
New York, NY
Jean-François Rossi
Eric Legouffe
Service d’Hematologie et d’Oncologie Medecale
CHU Lapeyronie
Montpellier, France
Zhao-Yang Lu
Michel Jourdan
U475, INSERM
Montpellier, France
Yuan Chang
Department of Pathology
Columbia University
New York, NY
Bernard Klein
Unité de Therapie Cellulaire
CHU Saint Eloi
Montpellier, France
REFERENCES


Cytoplasmic Interleukin-4 (IL-4) and Surface IL-4 Receptor Expression in Patients With B-Cell Lymphocytic Leukemia

To the Editor:

B-cell chronic lymphocytic leukemia (B-CLL) is a malignancy characterized by the accumulation of long-lived CD5+ cells in which cytokines might be involved in the proliferation and survival of malignant B cells.1–4

In particular, interleukin-4 (IL-4) prevents B-CLL cell clones from entering spontaneous apoptosis by increasing the expression of bcl-25 and protects B-CLL cells against anti-APO1-induced apoptosis.6 Only one report has analyzed the intracellular expression of IL-4 in T cells of patients with B-CLL.7 We examined the expression of IL-4 and IL-4 receptor (IL-4R) in unstimulated leukemic B cells and T cells from 10 patients with untreated stage A B-CLL and compared them with 10 normal controls using flow cytometric analyses.

We found that the proportion of CD19+ cells expressing cytoplasmic IL-4 was significantly higher in B-CLL patients than in controls (P < .002; Table 1). The proportion of CD3+ cells expressing cytoplasmic IL-4 was significantly higher in B-CLL patients than in controls (P < .02). Although the proportion of CD19+ cells expressing IL-4R was similar, the proportion of CD3+ cells expressing the IL-4R in B-CLL patients was significantly higher than in normal controls (P < .02). IL-4 could not be detected in the supernatant after the in vitro culture of the cells from both patients and controls. After stimulation with the mitogen PWM, six of the seven control samples and none of the patient cells had detectable supernatant IL-4R (P < .03; Table 2). The demonstration that T cells from B-CLL patients display a greater percentage of IL-4R expression from normal individuals is novel. It is unclear whether the T cells from B-CLL patients express both the IL-4R together with IL-4 or this aberrant expression occurs on different T-cell populations in these patients. It is intriguing that no increase in IL-4R expression could be found on malignant B-CLL cells despite the expression of cytoplasmic IL-4. It is possible that the IL-4 from the B-CLL B cells is released and taken up rapidly by the T cells, and this leads to the aberrant expression of the IL-4R. Alternatively, the interaction between the malignant B cells and T cells may occur in a microenvironment in which local concentrations of IL-4 may be high, but these are not reflected in the blood. The disproportionate relationship between IL-4 and its receptor in the normal T-cell compartment compared with the malignant B-cell compartment in B-CLL is presum-
Kaposi's Sarcoma-Associated Herpesvirus Is Not Detected With Immunosuppression in Multiple Myeloma

Karin Tarte, Sonja J. Olsen, Jean-François Rossi, Eric Legouffe, Zhao-Yang Lu, Michel Jourdan, Yuan Chang and Bernard Klein